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Activation of NQO1 in NQO1*2
polymorphic human leukemic HL‑60 cells
by diet‑derived sulforaphane
Joseph M. Wu*, Ardalan Oraee, Barbara B. Doonan, John T. Pinto and Tze‑chen Hsieh

Abstract
Background: The NAD(P)H: quinone oxidoreductase (NQO1) confers protection against semiquinones and also
elicits oxidative stress. The C609T polymorphism of the NQO1 gene, designated NQO1*2, significantly reduces its
enzymatic activity due to rapid degradation of protein. Since down regulation of NQO1 mRNA expression correlates
with increased susceptibility for developing different types of cancers, we investigated the link between leukemia and
the NQO1*2 genotype by mining a web-based microarray dataset, ONCOMINE. Phytochemicals prevent DNA damage
through activation of phase II detoxification enzymes including NQO1. Whether NQO1 expression/activity in leukemia
cells that carry the labile NQO1*2 genotype can be induced by broccoli-derived phytochemical sulforaphane (SFN) is
currently unknown.
Methods and Results: The ONCOMINE query showed that: (1) acute lymphoblastic leukemia and chronic myelog‑
enous leukemia are associated with reduced NQO1 levels, and (2) under-expressed NQO1 was found in human HL-60
leukemia cell line containing the heterozygous NQO1*2 polymorphism. We examined induction of NQO1 activity/
expression by SFN in HL-60 cells. A dose-dependent increase in NQO1 level/activity is accompanied by upregulation
of the transcription factor, Nrf2, following 1–10 μM SFN treatment. Treatment with 25 µM SFN drastically reduced
NQO1 levels, inhibited cell proliferation, caused sub-G1 cell arrest, and induced apoptosis, and a decrease in the levels
of the transcription factor, nuclear factor-κB (NFκB).
Conclusions: Up to 10 μM of SFN increases NQO1 expression and suppresses HL-60 cell proliferation
whereas ≥ 25 μM of SFN induces apoptosis in HL-60 cells. Further, SFN treatment restores NQO1 activity/levels in
HL-60 cells expressing the NQO1*2 genotype.
Keywords: Sulforaphane, NQO1, HL-60, Leukemia
Background
Cancer is the second most frequent cause of death worldwide, with a projected 70 % rise over the next two decades reaching an estimated 24 million new cancer cases
per year by 2035 [1, 2]. Genomic instability caused by
dysregulation of intracellular redox status that gives rise
to sustained oxidative stress is considered to be a risk factor for cancer [3, 4]. Quinones, present in the intra- and
extracellular compartments of almost all tissue types,
*Correspondence: Joseph_Wu@nymc.edu
Room 147, Department of Biochemistry and Molecular Biology, Basic
Sciences Building, New York Medical College, 15 Dana Road, Valhalla,
NY 10595, USA

contribute to cellular oxidative stress if they participate
in one-electron transfer reactions with concomitant formation of highly reactive semiquinones [5]. Accordingly,
half-reduced quinones can participate in the carcinogenic process by causing depurination of DNA nucleotide bases [6–8].
NAD(P)H:quinone oxidoreductase (NQO1) catalyzes
two-electron reduction of quinones [9] to products that
are readily excreted by conjugation with sulfate or glucuronic acid [10, 11]. Thus, NQO1 provides protection
against oxidative stress and exhibits versatility as a cytoprotective enzyme [12, 13]. In addition to conferring cellular protection, NQO1 counteracts DNA damage by
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preventing semiquinone generation caused by exposure
to certain xenobiotics and carcinogens, in particular,
benzo[a]pyrene-derived dihydrodiol epoxides and o-quinones derived from oxidized catechols [14–17]. NQO1
also controls cell proliferation and induction of apoptosis
by stabilizing the tumor suppressor protein, p53 [18, 19].
Multiple single-nucleotide polymorphisms (SNPs)
have been reported to cause a dysfunctional NQO1
gene [20, 21]. One extensively studied and significant
polymorphic variant is NQO1*2, which is characterized by a C609T (rs1800566, Pro187Ser) polymorphism
of the NQO1 gene [12, 22, 23]. Individuals carrying heterozygous or homozygous alleles of this genetic variant
manifest with the highly unstable NQO1*2 isoform, that
undergoes enhanced polyubiquitination and proteasomal degradation, resulting in decreased or complete loss
of NQO1 activity and a consequential increased susceptibility to cancer [24, 25]. The NQO1*2 polymorphism
has been widely investigated but limited information is
available on whether the NQO1*2 genotype is associated with specific types of cancers and whether it can be
a useful prognostic indicator for efficacy of chemoprevention in specific cancer models. In this communication, we examined microarray data from the Oncomine
database to investigate the correlation between underexpression of NQO1 and human leukemia. An apparent association of reduced NQO1 expression was found
among different types of leukemia specimens compared
to normal. Previous studies show that extracts of cruciferous vegetables, such as broccoli, contain antioxidant
phytochemicals that induce Nrf2-regulated cytoprotective genes including NQO1 and other phase II detoxification enzymes [26–28]. However, the ability of the
isothiocyanate SFN to induce NQO1 functionality in
NQO1*2 cancer cells remains largely unknown. Accordingly, we perform studies to address the following questions: (1) can the expression level of NQO1 provide a
surrogate measure for certain cancers and (2) can broccoli-derived SFN activate NQO1 expression in NQO1*2
cells? We provide evidence that SFN [29–31] can induce
NQO1 enzymatic activity and expression of the NQO1*2
polymorphic variant. SFN also upregulates a number of
cytoprotective enzymes involved in maintaining intracellular redox capacity [32, 33].

Methods
Oncomine analyses

The freely available web-based microarray dataset platform, Oncomine [34, 35], was used to examine the fold
change of NQO1 mRNA expression levels among leukemia samples. The keywords ‘NQO1’, ‘leukemia’, ‘HL-60’
and ‘clinical specimen’ were used to obtain the initial data
for evaluation. A further quality check was conducted
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using p < 0.01 as the statistical threshold; only samples
with NQO1 expression data that met this level of significance were included in the analyses.
Reagents

Sulforaphane was purchased from LKT Laboratories (St.
Paul, MO). Bovine serum albumin (BSA), menadione,
dicoumarol and NADPH were purchased from SigmaAldrich Corporation (St. Louis, MO). Primary antibodies
against NQO1, Keap1, Nrf2, NFκB p50, NFκB p65, IκB,
caspase 2, caspase 3, bcl-2, bax, actin, histone H1 and
secondary antibodies were purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). Anti-poly (ADPribose) polymerase (PARP) antibody was purchased from
Biomol International, L.P. (Plymouth Meeting, PA). Fetal
calf serum, RPMI-1640, penicillin and streptomycin were
purchased from Cellgro, Inc (Herndon, VA). All other
chemicals and solvents used were of analytical grade.
Cell culture and growth inhibition assay

Human promyelocytic leukemia cell line (HL-60) was
obtained from American Type Culture Collection
(Manassas, VA) and maintained in RPMI-1640 supplemented with penicillin, streptomycin and 10 % heat inactivated fetal calf serum, as previously described [36–38].
For treatment, cells were seeded at a density of 1 × 105
cells/ml. SFN dissolved in 1 N NaOH solution and neutralized with HCl, was added to the culture medium to
final concentrations of 0, 1, 2.5, 5.0, 10, and 25 μM. Cells
were treated with SFN and harvested at different times
post-treatment, as indicated in Figs. 1, 2, 3, 4. Cell viability was determined by trypan blue exclusion using a
hemocytometer. Cell pellets were stored at −80 °C for
biochemical and molecular analyses.
Preparation of cell extracts for immunoblot analysis

For immunoblotting experiments, cells were lysed in icecold RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 % Triton X-100, 1 % deoxycholate, 0.1 %
SDS, 1 mM dithiothreitol and 10 μl/ml protease inhibitor
cocktail). Cytosol, mitochondria and nuclear fractions for
the analysis of subcellular distribution of Keap1 and Nrf2
were isolated using commercially available kits (SigmaAldrich Corporation, St Louis, MO). Protein concentration
of cell lysates and fractionated cell extracts were determined by the Coomassie protein assay kit (Pierce Chemical Company, Rockford, IL) using BSA as a standard.
Immunoblotting

The cell lysates or extracts prepared from cell fractions
were resolved by 10 % SDS-PAGE and the proteins were
transferred to a nitrocellulose membrane and blocked
overnight at 4 °C in TBST buffer (10 mM Tris, pH 7.5,
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100 mM NaCl and 0.05 % Tween-20) containing 3 % nonfat dried milk. The blots were incubated with various
primary antibodies, followed by incubation for 1 h with
appropriate secondary antibodies. The expression levels
of actin and histone H1 were used as loading controls.
The intensity of the specific immunoreactive bands was
detected by enhanced chemiluminescence (ECL), quantified by densitometry and normalized against either actin
or histone H1, as previously described [38].
Cell cycle analysis

HL-60 cells treated with different concentrations of SFN
(0, 1, 2.5, 5, 10, and 25 μM) were assayed for changes
in cell cycle phase distribution using flow cytometry.
Cells were stained with 1.0 μg/ml DAPI (from SigmaAldrich Corporation, St. Louis, MO) at pH 6.8, as previously described [38, 39]. DNA content histograms were
obtained and the percentage of cells in the respective
phases (G1, S and G2/M) of the cell cycle was quantified. Cells undergoing apoptosis were estimated using the
appearance of the sub-G1 peak [38, 39].
Enzyme activity assays

For enzyme activity assays, cells were resuspended in icecold 50 mM potassium phosphate buffer (pH 7.4) containing 2 mM EDTA and sonicated. Subsequently, cell
suspensions were subjected to centrifugation at 13,000×g
for 10 min at 4 °C. The resulting supernatant fractions
were collected for the measurement of enzyme activities
shown below [40].
NQO1 activity assay

NQO1 activity was measured by the modified method
of Lind et al. [41]. Briefly, the reaction was started with
the addition of menadione into the reaction mixture
containing 33 mM potassium phosphate buffer (pH 7.4),
0.18 mM NADPH, 0.02 % BSA, 0.01 % Tween-20 and cell
lysates [40]. The oxidation of NADPH was monitored
spectrophotometrically at 340 nm, 25 °C for 2 min with
and without 20 μM dicoumarol. The dicoumarol-sensitive portion of the activity was regarded as a measure
of NQO1 activity, using the NADPH extinction coefficient (6.22 mM−1 cm−1) and defined as μmol of NADPH
oxidized·min−1·mg−1 protein.
Data analysis

The results are expressed as mean ± standard deviation
(SD). Differences among groups are assessed by one-way
analysis of variance using the SPSS software package for
Windows. Data among control and SFN-treated cells are
compared using the least significance difference (LSD)
test; statistical significance at p < 0.001 or < 0.01 is given
respective symbols in the figures.

Fig. 1 Effect of SFN on NQO1 protein expression and activity. a West‑
ern blot analysis of NQO1 protein expression in cell lysates treated
with 0, 1, 2.5, 5, 10 and 25 μM SFN for 24 and 48 h. b NQO1 enzyme
activity assay in cell lysates treated with 0, 1, 2.5, 5, 10 and 25 μM SFN
for 24 and 48 h. c Subcellular distribution of Keap 1 and Nrf2 in the
cytosol, mitochondria and nucleus in control and 48 h, SFN-treated
HL-60 cells. Actin and histone H1 were used as loading controls
for cytosolic and nuclear fractions, respectively. The intensity of
specific immunoreactive bands was quantified by densitometry and
expressed as fold differences against actin. Values of NQO1 enzyme
activities are mean ± SD for three experiments and activities of NQO1
are expressed as µmol of NADPH oxidized·min−1

Results
Survey NQO1 status using oncomine

The Oncomine database search was performed to examine the association of NQO1 mRNA expression levels
across different sub-type leukemia studies using the
reported p values and fold-changes. In two analyses that
compared clinical human tissue samples of normal vs
leukemia patients, under-expressed NQO1 was found in
human acute lymphoblastic leukemia (ALL) and chronic
myelogenous leukemia (CML) [42, 43] (Table 1). Since
rapid proteolysis of NQO1 occurred in the NQO1*2
isoform [44], low expression of NQO1 found in the
individuals with ALL and/or CML most likely carry
heterozygous or homozygous NQO1*2 alleles. Several
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Fig. 2 Effect of SFN on cell proliferation, viability and cell cycle control in HL-60 cells. a Cells were treated with 0, 10 and 25 μM SFN and the cell
numbers were determined at 6, 15, 24 and 48 h by counting using a hemocytometer. Cell viability was measured using the trypan blue exclusion
assay. Values are expressed as mean ± SD for three experiments, and asterisks * and ** shown above bars indicate statistical significance of p < 0.01
and p < 0.001, respectively, compared to vehicle-treated control. b, c Cells were treated with 0, 10 and 25 μM SFN for 24 and 48 h and analyzed by
flow cytometry. The cells in sub-G1 phase are used to estimate apoptotic cells

Fig. 3 Induction of apoptosis by SFN as determined by changes in
PARP cleavage, appearance of p-H2AX, decreases in pro-caspase 2
and pro-caspase 3. Western blot analysis revealed down regulation
of PARP expression as evidenced by appearance of the 89-kDa PARP
cleavage product, induction of p-H2AX, and down-regulation of both
pro-caspase 2 and pro-caspase 3 in ≥ 10 μM, 48 h SFN treated cells

leukemia cell lines are available and can be used as an
in vitro cell model to examine the activation of NQO1
expression in NQO1*2 cells. Our studies investigated
HL-60 leukemic cells, since previous PCR–RFLP analysis for the SNP (C609T) demonstrated that these cells
are heterozygous for the NQO1*2 polymorphism [45]. A

further search of the oncomine database involving cancer cell line panels indicated that NQO1 expression in
HL-60 cells is consistently low or absent (Table 2). Of 6
HL-60 cell studies queried in oncomine—four published
[46–49] and two unpublished (Compendia and Wooster
studies), low NQO1 expression consistently ranked in the
top 1–4 % of under-expressed genes [47]; this significant
reduction in NQO1 can be attributable to the presence of
genetic polymorphisms on C609T mutation [22, 44, 45,
50, 51]. Thus, our interrogation of the Oncomine microarray dataset platform provides support that HL-60 cells
can serve as an appropriate experimental model to study
the activation of NQO1 expression and function by broccoli-derived SFN.
Control of NQO1 in NQO1*2 cells by SFN is accompanied
by concomitant change in Nrf2

HL-60 cells were treated with varying doses of SFN for
different periods of time. Western blot analysis revealed
dose-dependent increases in NQO1 protein expression
with the greatest induction occurring after 24 h with
5–10 μM SFN and with 1 μM SFN sufficient to more
than double NQO1 levels after treatment for 24- and
48-h (Fig. 1a). Whereas, treatment with 25 μM SFN for
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Fig. 4 Effect of SFN on the changes of NFκB p65, p50, IκB, bcl-2 and
bax expression in HL-60 cells. a Western blot analysis revealed the
alteration on NFκB subunits p65/p50 and IκB expression in 48 h SFN
treated cells. b The total protein expression level of bax and bcl-2 was
determined by Western blot analysis and the normalized level of cel‑
lular bax and bcl-2 and alteration in the ratio of bax to bcl-2 in HL-60
cells treated for 48 h with increasing doses of SFN were calculated.
In a and b, the intensity of the specific immunoreactive bands were
quantified by densitometry and expressed as a fold difference against
actin (loading control)

Table 1 Comparison of NQO1 expression across 2 clinical
specimens as compared to levels in healthy tissue
Under-expressed NQO1
Cancer type Gene rank (%) p value

Fold change Reference

ALL

Top 1

8.27E−5

−1.138

CML

Top 5

1.29E−10 −1.619

KirschnerSchwabe [45]
Radich [46]

The mRNA expression levels of NQO1 were compared in normal vs different
clinical sub-types of leukemia patients using the reported gene ranks, p values,
and fold changes. The clinical specimen fold-change is defined as change in
NQO1 mRNA expression level in the leukemia tissue compared to NQO1 mRNA
expression level in corresponding normal tissue. Gene rank orders are generated
based on the p values obtained in differential gene expression analysis.
The gene expression data retrieved from the Oncomine compendium is log
transformed and the standard deviation was normalized to one

48-h had a significant inhibitory effect on NQO1 protein expression. These results are reflective of a hormetic response and suggest that 1–10 μM SFN is able to

induce NQO1 levels in HL-60 cells expressing NQO1*2
genotype.
We next examined whether the observed change in
NQO1 protein expression correlated with changes in
NQO1 enzymatic activity. As shown in Fig. 1b, treatment
with 10 μM SFN for 24- and 48-h revealed time-dependent increases in NQO1 enzyme activity. Conversely, SFN
treatment at 25 µM for 24- and 48-h resulted in a significant inhibitory effect on NQO1 activity which may correlate with inhibition of NQO1 protein expression that we
observed (Fig. 1b). Previous studies show that SFN targets
the transcription factor, Nrf2, by de-repressing its Keap1dependent ubiquitination and enabling stabilization and
subsequent nuclear translocation of Nrf2 to induce ARE
detoxification enzymes that includes NQO1 [52]. Therefore, we next investigated whether changes in NQO1
activity by SFN are due to alterations in the subcellular distribution of Keap1-Nrf2 in HL-60 cells. Western blot analysis data show that SFN treatment for 48 h down-regulates
cytosolic Keap1 accompanied by increases in nuclear Nrf2
in a dose-dependent manner (Fig. 1c). These results suggest that SFN enhances cytosol-to-nucleus translocation
of Nrf2 which partially supports the induction of NQO1
by SFN via Keap1-Nrf2 changes at 10 μM while the control
of NQO1 by SFN at 25 μM remains unclear.
Control of HL‑60 proliferation and cell cycle phase
transition by SFN

In addition to SFN controlling expression and activity of NQO1 in NQO1*2 HL-60 cells, we also examined whether SFN affects cell proliferation and viability.
Trypan blue exclusion assays were performed and results
showed time-dependent growth inhibition of HL-60 cells
by SFN after 24- and 48-h with an IC50 of approximately
10 μM at 48-h post-treatment (Fig. 2a). In addition,
time- and dose-dependent decreases in cell viability were
observed following 24- and 48-h treatments with 10 and
25 μM SFN as compared to control cells (Fig. 2a).
Cell cycle analyses were performed to determine
whether SFN alters cell cycle distribution. The percent
of cells in G1, S, and G2 phases was analyzed (Fig. 2b).
The amount of DNA in sub-G1 phase, indicative of DNA
fragmentation, was used to estimate cell death. As shown
in Fig. 2b, SFN treatment for 24 h caused a substantial
decrease in number of cells in S-phase and a concomitant increase in cells accumulating in sub-G1 phase (1.8 %
in control vs 34 and 63.5 % in cells treated with 10 and
25 μM SFN, respectively). Prolonged (48-h) exposure of
HL-60 cells to 10 and 25 μM SFN resulted in a significant
decrease of cells in both G1- and S-phases, and an accumulation of cells in sub-G1 phase (Fig. 2c). These results
suggest that SFN inhibits cell proliferation through cell
cycle arrest and induces apoptotic cell death.
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Table 2 Comparison of NQO1 expression in HL-60 across 6
analyses using human cancer cell lines
Under-expressed NQO1
Cell line

Gene rank (%) p value

Fold change Reference

HL-60

Top 1

1.76E−98

HL-60

Top 2

1.08E−4

HL-60

Top 2

1.09E−4

HL-60

Top 2

Barretina [47]

HL-60

Top 2

1.73E−62 −11.959

HL-60

Top 4

−3.978

Garnett [48]

−7.291

Compendia (not
published)

−7.395

Shankavaram [49]

1.47E−17

−4.235

Wooster (not
published)

8.21E−5

−6.637

Lee [50]

The mRNA expression levels of NQO1 in the HL-60 cell line were investigated.
The fold-change is defined as decrease in level of NQO1 mRNA expression
in the HL-60 or in different leukemia cells compared to expression levels
in non-leukemic cell lines. Gene rank orders are generated based on the p
values obtained in differential gene expression analysis. The gene expression
data retrieved from the oncomine compendium are log transformed and the
standard deviation were normalized to one

Control of apoptotic induction and apoptogenic gene
expression by SFN in HL‑60 cells

Induction of apoptosis by SFN was revealed by the
appearance of sub-G1 fraction (Fig. 2); biochemical
analysis on SFN-induced apoptosis was further investigated by changes in PARP. Dose-dependent decreases
in PARP expression and the appearance of the distinct
PARP cleavage product were observed in HL-60 cells
treated with 25 μM SFN for 48 h (Fig. 3). Corroborative
evidence of induction of apoptosis by SFN was further
observed by a dose-dependent induction of p-H2AX, a
phosphorylated histone which usually marks doublestranded DNA breaks (Fig. 3a) [53, 54]. In addition, the
pro-apoptotic potential of SFN was also examined by
changes in caspase activation. Treatment with SFN for
48 h decreases pro-caspase 2 as well as pro-caspase 3
expression, indicative of their conversion to active execution caspases that are critical to the induction of apoptosis (Fig. 3). Taken together, SFN-induced apoptosis
in HL-60 cells was supported by induction of p-H2AX
expression, PARP cleavage, and caspase mediated cell
death.
Control of anti‑apoptotic gene expression by SFN in HL‑60
cells

A previous study demonstrated that SFN triggers TNFá-induced apoptosis through inhibition of NFκB and
activation of caspase-3 in leukemia cells [55]. We further
examined the control of NFκB by SFN in HL-60 leukemia cells. Cells were treated with 10 and 25 μM of SFN
for 48 h and changes on p65/p50 subunits of NFκB and
its inhibitor (IκB) were determined. SFN significantly
reduced expression of p50 subunits whereas minimum

changes in IκB expression were observed (Fig. 4a). Altering the combination of dimers within NFκB can disrupt
its transcriptional activity by preventing other transcriptionally active NFκB dimers from binding to κB transcription sites or facilitating recruitment of deacetylases
to promoter regions [56]. Thus, SFN inhibits NFκB activity by modifying its heterodimer p65/p50. NFκB regulates the expression of anti-apoptosis proteins including
bcl-2, and the ratio between bcl-2 and its corresponding apoptosis agonist, bax regulates a biological pathway responsible for cell death. Accordingly, we further
examined the expression of bax and bcl-2 in HL-60 cells
in response to SFN treatment [57]. As shown in Fig. 4b,
incubation of HL-60 cells with 10 μM SFN for 48 h
induced bax over-expression. This was accompanied by a
concomitant decrease of bcl-2 which led to an increase
in the bax/bcl-2 ratio favoring cell death suggesting that
induction of apoptosis by SFN is partially through NFκB
mediated down regulation of bcl-2.

Discussion
SNPs are widely observed in the human population
and may vary from nonsynonymous to synonymous to
manifestations occurring in the noncoding region of the
human genome. SNPs can exert influences on gene promoter activity and hence the transcription of mRNAs as
well as their conformation and stability. In addition, SNPs
can alter the subcellular localization of mRNAs and/or
proteins and hence can manifest clinically as diseases in
humans. Silencing of genes due to SNPs is also known to
occur in eukaryotes and mammalian systems.
NQO1 is affected by several common SNPs of which
the C609T serine-to-proline substitution, known
as NQO1*2, shows significant correlation with cancer susceptibility [20, 24]. Genotyped individuals who
are homozygous for the NQO1*2 polymorphism have
silenced NQO1 expression and almost complete loss
of NQO1 enzymatic activity, while those genotyped as
heterozygous show reduced levels of NQO1 activity
and protein expression. Two human hematopoietic cell
lines, HL-60 (promyelocytic leukemia) and Raji (Burkitt’s
lymphoma), both show similar, substantial reduction of
NQO1 transcript levels [45]; phenotypically, however, a
complete loss of NQO1 activity was only evident in Raji,
while the HL-60 cells expressed a low level of enzyme
activity. One interpretation of these discordant findings
is that while the expression of NQO1 is controlled by a
transcriptional mechanism in both cell types, in the Raji
cell line the dominant control may lie in the post-transcriptional proteolytic degradation of NQO1 and that
this regulatory feature is not shared by HL-60 cells [44].
This may be viewed in light of various genetic allele contrast models (C vs T), i.e., dominant (CC vs CT + TT),

Wu et al. Exp Hematol Oncol (2016) 5:27

recessive (CC + CT vs TT), homozygous co-dominant
(CC vs TT), and heterozygous co-dominant (CC vs CT).
In particular, the NQO1 609CT + TT genotype is more
common in ALL patients than in controls. Carriers of
the variant T allele exhibit a 2.64-fold increased risk for
cancer development [58]. These results are in agreement
with previously published studies that report underexpression of NQO1 in leukemia (specifically, HL-60
cells) with low NQO1 transcript levels [59, 60]. Thus,
our studies using HL-60 to test and advance the feasibility that isothiocyanates in particular SFN can reactivate
NQO1 gene expression and activity in NQO1*2 cells.
Restoration of NQO1 activity has important implications not only for cytoprotection of cells but also for
increasing the sensitivity of cells to chemotherapeutic
agents such as β-lapachone or mitomycin C. Traditional
metabolic studies on NQO1 have regarded two-electron
reductions of quinones to hydroquinones as a detoxification mechanism because it circumvents formation
of highly reactive semiquinones. In reality, the chemical
nature of the quinone and/or hydroquinone will dictate
whether the effect involves a toxification or a detoxification reaction. Two-electron reductions of both synthetic
and naturally-occurring quinones can induce toxicity in
cancer cells. Thus, NQO1 can mediate a futile two-electron cycling between the oxidized quinone forms of the
aforementioned drugs and their two-electron reduced
hydroquinone forms to induce tumor cell death [12,
61]. The bioactivation of a quinone-containing prodrug
such as mitomycin C by NQO1 can be attenuated or
nulled in individuals with the heterozygous (CC vs CT)
or homozygous (TT vs CC) NQO1*2 genotype, respectively [62]. Results of the NQO1 enzyme activity assay,
in combination with a robust expression of the NQO1
protein (see western blot Fig. 1a, b), clearly show restoration/induction of NQO1 protein expression and activity in cancer types expressing low levels of the protein,
specifically in NQO1*2 (HL-60) cancer cells. Thus, the
demonstration that low NQO1 expression levels could
be substantially increased through the use of chemopreventive agents such as SFN, which has much potential for
implication in anticancer prodrug therapy.
In support of prodrug idea and the potential application of NQO1 status as a biomarker for certain cancers, we examined microarray data from the Oncomine
database to further investigate the association between
NQO1*2 and human cancer. Under-expression of NQO1
transcription has been observed in virtually all lymphoma
cancer types. Of note, downregulation of NQO1 was
found in follicular lymphoma and Burkitt’s lymphoma
[45] and, in a series of three lymphoma cell lines, underexpression of NQO1 transcription was shown to correlate with decreased sensitivity to the chemotherapeutic
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agents: mitomycin C, fluorouracil, and benzoquinone
ansamycins e.g. geldanamycin.
Moreover, several instances of substantially diminished NQO1 levels in human sarcoma samples were
also observed. Statistically significant under-expression
of NQO1 was discovered in liposarcoma and soft tissue
sarcoma. In particular, a difference in NQO1 expression
was found between cases of liposarcoma with wild-type
or mutant p53. Specifically, the liposarcoma samples with
mutant p53 exhibited 3-fold lower levels of NQO1 than
those with wild-type p53. These results are comparable
with previously published data which show that mutant
p53 is associated with diminished levels of NQO1 and
other phase II detoxification enzymes [63]. As a result
of the potent tumor suppressive functions of wild-type
p53, any factor that disrupts p53 stability may attenuate
wild-type activity and contribute to cell transformation
and carcinogenesis. This is of prime importance because
NQO1 stabilizes p53 and prevents its degradation [18,
64–66].
In summary, the present study supports the emerging
fields of nutrigenomics and nutrigenetics that describe
the ability of specific nutrients to activate intracellular signaling pathways. We demonstrate that low
NQO1 expression, as found in human leukemic HL-60
cells harboring the polymorphic NQO1*2 variant can
be reactivated by physiologically achievable doses of
SFN via a mechanism involving the activation of Nrf2mediated transcription signaling control. It is noteworthy that in nutrigenomic studies comparing potency
of phytochemicals, SFN exhibits the highest potency
determined by its “CD value”, defined as the concentration of a compound required to double NQO1 specific
activity in Hepa 1c1c7 murine hepatoma cells [67, 68].
The concentration of SFN required to double the activity of NQO1 is as low as 0.2 μM. Although some studies indicate that high doses of phytonutrients provide
the greatest cytoprotective effects, our studies confirm
the findings of others that lower doses of SFN may have
greater efficacy [69].
Diets rich in SFN or its precursor may result in bioavailable amounts that are sufficient to overcome the
“CD” threshold required to reactivate NQO1*2 to expression levels comparable to that of the NQO1 genotype
for treatment of patients with leukemia. Characterizing
responders to neoadjuvant therapy would be particularly
beneficial in population groups known to have a high
prevalence of the homozygous NQO1*2 genotype [70].
Knowledge of the CD threshold is critical to minimize
overtreatment by improving efficacy of cancer chemotherapy and/or avoid unnecessary delay of treatment in
alleviating cancer susceptibility. These possibilities warrant further research and are under active consideration.

Wu et al. Exp Hematol Oncol (2016) 5:27

Conclusions
Important findings addressed are (1) Oncomine mining is
a valuable and useful approach to guide future research,
(2) SNP-associated NQO1 levels of expression can serve
as a biomarker for certain cancers and (3) SFN can activate NQO1 expression in NQO1*2 cells.

Page 8 of 9

9.
10.
11.

12.
Abbreviations
NQO1, NAD(P)H: quinone oxidoreductase 1; SFN: sulforaphane; Nrf2: nuclear
factor (erythroid-derived 2)-like 2; NFκB: nuclear factor-κB; SNPs: singlenucleotide polymorphisms; Keap1: kelch-like ECH-associated protein 1; PARP:
poly(ADP-ribose) polymerase; p-H2AX: phosphorylated histone H2AX; IκB:
inhibitor of κB; bcl-2: Bcl-2 (B cell lymphoma 2; BSA: bovine serum albumin;
ECL: enhanced chemiluminescence; ALL: acute lymphoblastic leukemia; CML:
chronic myelogenous leukemia; ARE: antioxidant response element; CD value:
the concentration of a compound required to double NQO1 specific activity
in Hepa 1c1c7 murine hepatoma cells.
Authors’ contributions
TCH supervised and performed the laboratory experiments and Oncomine
analysis. AO performed Oncomine query under supervision of TCH. TCH. AO
and JMW designed the research, analyzed the data, and wrote the manuscript.
BD, JTP edited and corrected the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This research was supported in part by the Intramural Sponsored Research
Program of New York Medical College to T.C.H. Jan Kunicki provided assistance
in flow cytometry.

13.
14.

15.
16.

17.

18.
19.

Competing interests
The authors declare that they have no competing interests.
Funding
This research was made possible with support provided in part by the
Intramural Sponsored Research Program of New York Medical College to TCH.
The authors declare that the funding source has no role in the design of the
study and collection, analysis, and interpretation of data and in writing the
manuscript.
Received: 4 August 2016 Accepted: 30 August 2016

20.

21.
22.
23.
24.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.
2016;66:7–30.
2. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and
mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev.
2016;25:16–27.
3. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative
damage in carcinogenesis. Toxicol Pathol. 2010;38:96–109.
4. Sainz RM, Lombo F, Mayo JC. Radical decisions in cancer: redox control of
cell growth and death. Cancers (Basel). 2012;4:442–74.
5. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones
in toxicology. Chem Res Toxicol. 2000;13:135–60.
6. Cavalieri EL, Rogan EG. A unifying mechanism in the initiation of
cancer and other diseases by catechol quinones. Ann NY Acad Sci.
1028;247–257:2004.
7. Zahid M, Saeed M, Rogan EG, Cavalieri EL. Benzene and dopamine
catechol quinones could initiate cancer or neurogenic disease. Free Radic
Biol Med. 2011;48:318–24.
8. Cavalieri E, Saeed M, Zahid M, Cassada D, Snow D, Miljkovic M, et al.
Mechanism of DNA depurination by carcinogens in relation to cancer
initiation. IUBMB Life. 2012;64:169–79.

25.
26.
27.
28.
29.

30.

Bianchet MA, Erdemli SB, Amzel LM. Structure, function, and mechanism
of cytosolic quinone reductases. Vitam Horm. 2008;78:63–84.
Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. Identification of a novel intestinal
first pass metabolic pathway: NQO1 mediated quinone reduction and
subsequent glucuronidation. Curr Drug Metab. 2007;8:137–49.
Cassagnes LE, Perio P, Ferry G, Moulharat N, Antoine M, Gayon R, et al. In
cellulo monitoring of quinone reductase activity and reactive oxygen
species production during the redox cycling of 1,2 and 1,4 quinones. Free
Radic Biol Med. 2015;89:126–34.
Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the
sensitivity and resistance to antitumor quinones. Biochem Pharmacol.
2012;83:1033–40.
Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreduc‑
tase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally
versatile cytoprotector. Arch Biochem Biophys. 2010;501:116–23.
Long DJ 2nd, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)
H:quinone oxidoreductase 1 deficiency and increased susceptibility to
7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin.
J Natl Cancer Inst. 2001;93:1166–70.
Shen J, Barrios RJ, Jaiswal AK. Inactivation of the quinone oxidoreductases
NQO1 and NQO2 strongly elevates the incidence and multiplicity of
chemically induced skin tumors. Cancer Res. 2010;70:1006–14.
Chandrasena RE, Edirisinghe PD, Bolton JL, Thatcher GR. Problematic
detoxification of estrogen quinones by NAD(P)H-dependent quinone
oxidoreductase and glutathione-S-transferase. Chem Res Toxicol.
2008;21:1324–9.
Singh B, Bhat NK, Bhat HK. Induction of NAD(P)H-quinone oxidoreduc‑
tase 1 by antioxidants in female ACI rats is associated with decrease in
oxidative DNA damage and inhibition of estrogen-induced breast cancer.
Carcinogenesis. 2012;33:156–63.
Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a
distinct pathway. Proc Natl Acad Sci USA. 2002;99:3099–104.
Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, et al. Interac‑
tion of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the
tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem.
2003;278:10368–73.
Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K,
et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is
a strong prognostic and predictive factor in breast cancer. Nat Genet.
2008;40:844–53.
Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H:quinone
oxidoreductase (NQO1) polymorphism, exposure to benzene, and predis‑
position to disease: a HuGE review. Genet Med. 2002;4:62–70.
Ross D. Quinone reductases multitasking in the metabolic world. Drug
Metab Rev. 2004;36:639–54.
Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA.
NQO1 polymorphisms and de novo childhood leukemia: a HuGE review
and meta-analysis. Am J Epidemiol. 2008;168:1221–32.
Freriksen JJ, Salomon J, Roelofs HM, Te Morsche RH, van der Stappen JW,
Dura P, et al. Genetic polymorphism 609 C > T in NAD(P)H:quinone oxi‑
doreductase 1 enhances the risk of proximal colon cancer. J Hum Genet.
2014;59:381–6.
Lienhart WD, Gudipati V, Uhl MK, Binter A, Pulido SA, Saf R, et al. Collapse
of the native structure caused by a single amino acid exchange in human
NAD(P)H:quinone oxidoreductase(1.). FEBS J. 2014;281:4691–704.
Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcino‑
genic protective enzymes from broccoli: isolation and elucidation of
structure. Proc Natl Acad Sci USA. 1992;89:2399–403.
Talalay P. Chemoprotection against cancer by induction of phase 2
enzymes. BioFactors. 2000;12:5–11.
Tortorella SM, Royce SG, Licciardi PV, Karagiannis TC. Dietary sulforaphane
in cancer chemoprevention: the role of epigenetic regulation and HDAC
inhibition. Antioxid Redox Signal. 2015;22:1382–424.
Dinkova-Kostova AT, Fahey JW, Wade KL, Jenkins SN, Shapiro TA, Fuchs
EJ, et al. Induction of the phase 2 response in mouse and human skin
by sulforaphane-containing broccoli sprout extracts. Cancer Epidemiol
Biomarkers Prev. 2007;16:847–51.
Wagner AE, Ernst I, Iori R, Desel C, Rimbach G. Sulforaphane but not
ascorbigen, indole-3-carbinole and ascorbic acid activates the transcrip‑
tion factor Nrf2 and induces phase-2 and antioxidant enzymes in human
keratinocytes in culture. Exp Dermatol. 2010;19:137–44.

Wu et al. Exp Hematol Oncol (2016) 5:27

31. Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E. Differential effects of
sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in
normal prostate cells versus hyperplastic and cancerous prostate cells.
Mol Nutr Food Res. 2011;55:999–1009.
32. Ahn YH, Hwang Y, Liu H, Wang XJ, Zhang Y, Stephenson KK, et al. Electro‑
philic tuning of the chemoprotective natural product sulforaphane. Proc
Natl Acad Sci U S A. 2010;107:9590–5.
33. Guo S, Cheng X, Lim JH, Liu Y, Kao HY. Control of antioxidative response
by the tumor suppressor protein PML through regulating Nrf2 activity.
Mol Biol Cell. 2014;25:2485–98.
34. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al.
ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia. 2004;6:1–6.
35. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs
BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of
18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–80.
36. DiPietrantonio AM, Hsieh TC, Wu JM. Specific processing of poly(ADPribose) polymerase, accompanied by activation of caspase-3 and eleva‑
tion/reduction of ceramide/hydrogen peroxide levels, during induction
of apoptosis in host HL-60 cells infected by the human granulocytic
ehrlichiosis (HGE) agent. IUBMB Life. 2000;49:49–55.
37. Hsieh TC, Kunicki J, Darzynkiewicz Z, Wu JM. Effects of extracts of
Coriolus versicolor (I’m-Yunity) on cell-cycle progression and expression
of interleukins-1 beta,-6, and -8 in promyelocytic HL-60 leukemic cells
and mitogenically stimulated and nonstimulated human lymphocytes. J
Altern Complement Med. 2002;8:591–602.
38. Hsieh TC, Wu P, Park S, Wu JM. Induction of cell cycle changes and
modulation of apoptogenic/anti-apoptotic and extracellular signaling
regulatory protein expression by water extracts of I’m-Yunity (PSP). BMC
Complement Altern Med. 2006;6:30.
39. Selvakumar E, Hsieh TC. Regulation of cell cycle transition and induction
of apoptosis in HL-60 leukemia cells by lipoic acid: role in cancer preven‑
tion and therapy. J Hematol Oncol. 2008;1:4.
40. Elangovan S, Hsieh TC. Control of cellular redox status and upregulation
of quinone reductase NQO1 via Nrf2 activation by alpha-lipoic acid in
human leukemia HL-60 cells. Int J Oncol. 2008;33:833–8.
41. Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification,
properties, and function. Methods Enzymol. 1990;186:287–301.
42. Kirschner-Schwabe R, Lottaz C, Todling J, Rhein P, Karawajew L, Eckert C,
et al. Expression of late cell cycle genes and an increased proliferative
capacity characterize very early relapse of childhood acute lymphoblastic
leukemia. Clin Cancer Res. 2006;12:4553–61.
43. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expres‑
sion changes associated with progression and response in chronic
myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794–9.
44. Scarpa ES, Bonfili L, Eleuteri AM, La Teana A, Bruge F, Bertoli E, et al. ATP
independent proteasomal degradation of NQO1 in BL cell lines. Bio‑
chimie. 2012;94:1242–9.
45. Bruge F, Virgili S, Cacciamani T, Principi F, Tiano L, Littarru GP. NAD(P)
H:quinone oxidoreductase (NQO1) loss of function in Burkitt’s lymphoma
cell lines. BioFactors. 2008;32:71–81.
46. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S,
et al. The cancer cell line encyclopedia enables predictive modelling of
anticancer drug sensitivity. Nature. 2012;483:603–7.
47. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW,
et al. Systematic identification of genomic markers of drug sensitivity in
cancer cells. Nature. 2012;483:570–5.
48. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK,
et al. Transcript and protein expression profiles of the NCI-60 cancer cell
panel: an integromic microarray study. Mol Cancer Ther. 2007;6:820–32.
49. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J,
et al. A strategy for predicting the chemosensitivity of human can‑
cers and its application to drug discovery. Proc Natl Acad Sci USA.
2007;104:13086–91.
50. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, MPO
and CYP2E1 genetic polymorphisms in the susceptibility to childhood
acute lymphoblastic leukemia. Int J Cancer. 2002;97:230–6.
51. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves
MF, United Kingdom Childhood Cancer Study Investigators. A lack
of a functional NAD(P)H:quinone oxidoreductase allele is selectively

Page 9 of 9

52.
53.
54.
55.

56.
57.
58.

59.
60.

61.

62.

63.

64.
65.
66.
67.

68.
69.
70.

associated with pediatric leukemias that have MLL fusions. Cancer Res.
1999;59:4095–9.
Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen
JG, et al. Keap1-nrf2 signaling: a target for cancer prevention by sul‑
foraphane. Top Curr Chem. 2013;329:163–77.
Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular
marker of DNA damage and repair. Leukemia. 2010;24:679–86.
Rajendran P, Ho E, Williams DE, Dashwood RH. Dietary phytochemicals,
HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin
Epigenetics. 2011;3:4.
Moon DO, Kim MO, Kang SH, Choi YH, Kim GY. Sulforaphane suppresses
TNF-alpha-mediated activation of NF-kappaB and induces apoptosis
through activation of reactive oxygen species-dependent caspase-3.
Cancer Lett. 2009;274:132–42.
Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear
NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol
Cell. 2002;9:625–36.
Huang DC, O’Reilly LA, Strasser A, Cory S. The anti-apoptosis function of
Bcl-2 can be genetically separated from its inhibitory effect on cell cycle
entry. EMBO J. 1997;16:4628–38.
Yamaguti GG, Lourenco GJ, Silveira VS, Tone LG, Lopes LF, Lima CS.
Increased risk for acute lymphoblastic leukemia in children with
cytochrome P450A1 (CYP1A1)- and NAD(P)H: quinone oxidoreductase 1
(NQO1)-inherited gene variants. Acta Haematol. 2010;124:182–4.
Tudor G, Gutierrez P, Aguilera-Gutierrez A, Sausville EA. Cytotoxicity and
apoptosis of benzoquinones: redox cycling, cytochrome c release, and
BAD protein expression. Biochem Pharmacol. 2003;65:1061–75.
Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD.
Reductase enzyme expression across the National Cancer Institute Tumor
cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl
Cancer Inst. 1996;88:259–69.
Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, et al. Modulating endog‑
enous NQO1 levels identifies key regulatory mechanisms of action
of beta-lapachone for pancreatic cancer therapy. Clin Cancer Res.
2011;17:275–85.
Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for
NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones:
identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed
antitumor agent. Clin Cancer Res. 1998;4:3083–8.
Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, et al.
Mutant p53R273H attenuates the expression of phase 2 detoxifying
enzymes and promotes the survival of cells with high levels of reactive
oxygen species. J Cell Sci. 2012;125:5578–86.
Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability
and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc
Natl Acad Sci USA. 2001;98:1188–93.
Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-inde‑
pendent p53 proteasomal degradation regulated by NQO1. Proc Natl
Acad Sci USA. 2002;99:13125–30.
Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-inde‑
pendent proteasomal degradation of the tumor suppressors p53 and
p73. Genes Dev. 2005;19:316–21.
Fahey JW, Stephenson KK, Dinkova-Kostova AT, Egner PA, Kensler TW, Tala‑
lay P. Chlorophyll, chlorophyllin and related tetrapyrroles are significant
inducers of mammalian phase 2 cytoprotective genes. Carcinogenesis.
2005;26:1247–55.
Houghton CA, Fassett RG, Coombes JS. Sulforaphane and other nutrig‑
enomic Nrf2 activators: can the clinician’s expectation be matched by the
reality? Oxid Med Cell Longev. 2016;2016:7857186.
Pagliaro B, Santolamazza C, Simonelli F, Rubattu S. Phytochemical com‑
pounds and protection from cardiovascular diseases: a state of the art.
Biomed Res Int. 2015;2015:918069.
Ross D, Zhou H. Relationships between metabolic and non-meta‑
bolic susceptibility factors in benzene toxicity. Chem Biol Interact.
2010;184:222–8.

